Clinical Trials

    To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

    Investigator: William Ondo

    Study Coordinator: Daniel Arnaud Dominguez

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06553027

    Phone: 346.356.3635

    Protocol Number: PRO00038504

    Description


    This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.